Bionomics Ltd (BNO)

Sydney
0.053
+0.001(+1.92%)
  • Volume:
    34,627
  • Bid/Ask:
    0.053/0.057
  • Day's Range:
    0.053 - 0.053
Earnings results expected tomorrow

BNO Overview

Prev. Close
0.052
Day's Range
0.053-0.053
Revenue
-
Open
0.053
52 wk Range
0.044-0.205
EPS
-0.02
Volume
34,627
Market Cap
71.73M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
417,365
P/E Ratio
-
Beta
2.58
1-Year Change
-72.82%
Shares Outstanding
1,353,350,744
Next Earnings Date
17 Aug 2022
What is your sentiment on Bionomics?
or
Vote to see community's results!

Bionomics Ltd News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Bionomics Ltd Company Profile

Bionomics Ltd Company Profile

Employees
0
Market
Australia

Bionomics Limited (Bionomics) is an Australia-bases clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of novel, ion channel targeting drug candidates designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders. The Company operates in drug development segment in Australia. The Company is advancing its lead drug candidate, BNC210, which is an oral, proprietary, selective negative allosteric modulator of the a7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). The Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuyStrong Sell
Technical IndicatorsBuyBuyStrong BuyBuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyBuyStrong Sell